Genetic markers in oligodendroglial tumours

Gilbert MR, Lang FF. Management of patients with low-grade gliomas. Neurol Clin 2007; 25: 1073-88.10.1016/j.ncl.2007.07.007Search in Google Scholar

Strojnik T, Gornik-Kramberger K. [Stereotactic biopsy of brain tumours - Maribor experience with MHT stereotaxy system]. [Slovenian]. Zdrav Vestn 2008; 77: 601-8.Search in Google Scholar

Asthagiri AR, Pouratian N, Sherman J, Ahmed G, Shaffrey ME. Advances in brain tumor surgery. Neurol Clin 2007; 25: 975-1003. Engelhard HH, Stelea A, Mundt A. Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment and prognosis. Surg Neurol 2003; 60: 443-56.10.1016/S0090-3019(03)00167-8Search in Google Scholar

Strojnik A. Search of the shortest regimen: fractionation of a fully isoeffective combination of hyperfractionated and hypofractionated treatment. Radiol Oncol 2008; 42: 170-2.10.2478/v10019-008-0011-7Search in Google Scholar

Heikal AA, Wachowicz K, Thomas SD, Fallone BG. A phantom to assess the accuracy of tumor delineation using MRSI. Radiol Oncol 2008; 42: 232-9.10.2478/v10019-008-0015-3Search in Google Scholar

Giampaoli S. Epidemiology of major age-related diseases in women compared to men. Aging (Milano) 2000; 12: 93-105.10.1007/BF0333989610902051Search in Google Scholar

Pytel P, Lukas RV. Update on diagnosic practice: tumors of the nervous system. Arch Pathol Lab Med 2009; 133: 1062-77.10.5858/133.7.106219642733Search in Google Scholar

van den Bent MJ, Reni M, Gatta G, Vecht C. Oligodendroglioma. Crit Rev Oncol Hematol 2008; 66: 262-72.10.1016/j.critrevonc.2007.11.00718272388Search in Google Scholar

Siker ML, Chakravarti A, Mehta MP. Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma? Crit Rev Oncol Hematol 2006; 60: 99-111.10.1016/j.critrevonc.2006.04.00517027279Search in Google Scholar

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. WHO classification of tumours of the central nervous system. Lyon 2007: WHO, IARC; 2007. p. 53-67.10.1007/s00401-007-0278-6Search in Google Scholar

Ohgaki H. Epidemiology of brain tumors. Methods Mol Biol 2009; 472: 323-42.10.1007/978-1-60327-492-0_1419107440Search in Google Scholar

Cancer incidence in Slovenia 2005. Ljubljana: Institute of Oncology Ljubljana, Cancer Registry of Slovenia; 2008.Search in Google Scholar

Kachanov DY, Dobrenkov KV, Shamanskaya TV, Abdullaev RT, Inushkina EV, Savkova RF, et al. Solid tumors in young children in Moscow Region of Russian Federation. Radiol Oncol 2008; 42: 39-44.10.2478/v10019-007-0037-2Search in Google Scholar

Wrensch M, Fisher JL, Schwartzbaum JA, Bondy M, Berger M, Aldape KD. The molecular epidemiology of gliomas in adults. Neurosurg Focus 2005; 19: E5.10.3171/foc.2005.19.5.6Search in Google Scholar

Wrensch M, Minn Y, Chew T, Bondy M, Berger MS. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 2002; 4: 278-99.10.1093/neuonc/4.4.278Search in Google Scholar

Hilton DA, Melling C. Genetic markers in teh assesment of intrinsic brain tumours. Current Diagnostic Pathology 2004; 10: 83-92.10.1016/j.cdip.2004.01.002Search in Google Scholar

Scelsi R. Epidemiology of cerebral gliomas. Minerva Med 1984; 75: 1259-63.Search in Google Scholar

Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol 2006; 1: 97-117.10.1146/annurev.pathol.1.110304.100043Search in Google Scholar

Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999; 17: 2572-8.10.1200/JCO.1999.17.8.2572Search in Google Scholar

Engelhard HH, Stelea A, Cochran EJ. Oligodendroglioma: pathology and molecular biology. Surg Neurol 2002; 58: 111-7.10.1016/S0090-3019(02)00751-6Search in Google Scholar

Engelhard HH, Stelea A, Mundt A. Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. Surg Neurol 2003; 60: 443-56.10.1016/S0090-3019(03)00167-8Search in Google Scholar

Figarella-Branger D, Colin C, Coulibaly B, Quilichini B, Maues De Paula A, Fernandez C, et al. Histological and molecular classification of gliomas. Rev Neurol (Paris) 2008; 164: 505-15.10.1016/j.neurol.2008.03.01118565348Search in Google Scholar

Zustovich F, Della Puppa A, Scienza R, Anselmi P, Furlan C, Cartei G. Metastatic oligodendrogliomas: a review of the literature and case report. Acta Neurochir (Wien) 2008; 150: 699-703.10.1007/s00701-008-1507-z18548193Search in Google Scholar

Volavsek M, Lamovec J, Popović M. Extraneural metastases of anaplastic oligodendroglial tumors. Pathol Res Pract 2009; 205: 502-7.10.1016/j.prp.2008.11.003Search in Google Scholar

Bromberg JE, van den Bent MJ. Oligodendrogliomas: molecular biology and treatment. Oncologist 2009; 14: 155-63.10.1634/theoncologist.2008-0248Search in Google Scholar

van den Bent MJ. Diagnosis and management of oligodendroglioma. Semin Oncol 2004; 31: 645-52.10.1053/j.seminoncol.2004.07.006Search in Google Scholar

Franko A, Holjar-Erlic I, Miletic D. Lateral ventricle epidermoid. Radiol Oncol 2008; 42: 66-8.10.2478/v10019-008-0002-8Search in Google Scholar

Bisof V, Juretic A, Saric N, Melada A, Perkovic Z, Rados M, et al. Pituitary metastasis of renal cell carcinoma: a case report. Radiol Oncol 2008; 42: 225-31.10.2478/v10019-008-0017-1Search in Google Scholar

Liigant A, Haldre S, Oun A, Linnamägi U, Saar A, Asser T, et al. Seizure disorders in patients with brain tumors. Eur Neurol 2001; 45: 46-51.10.1159/000052089Search in Google Scholar

Engelhard HH. Current diagnosis and treatment of oligodendroglioma. Neurosurg Focus 2002; 12: E2.10.3171/foc.2002.12.2.3Search in Google Scholar

Celli P, Nofrone I, Palma L, Cantore G, Fortuna A. Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 1994; 35: 1018-35.10.1227/00006123-199412000-00003Search in Google Scholar

Burton EC, Prados MD. Malignant gliomas. Curr Treat Options Oncol 2000; 1: 459-68.10.1007/s11864-000-0073-2Search in Google Scholar

Gannett DE, Wisbeck WM, Silbergeld DL, Berger MS. The role of post-operative irradiation in the treatment of oligodendroglioma. Int J Radiat Oncol Biol Phys 1994; 30: 567-73.10.1016/0360-3016(92)90942-BSearch in Google Scholar

Paleologos NA, Cairncross JG. Treatment of oligodendroglioma: an update. Neuro Oncol 1999; 1: 61-8.10.1215/15228517-1-1-61Search in Google Scholar

Bullard DE, Rawlings CE 3rd, Phillips B, Cox EB, Schold SC Jr, Burger P, et al. Oligodendroglioma. An analysis of the value of radiation therapy. Cancer 1987; 60: 2179-88.10.1002/1097-0142(19871101)60:9<2179::AID-CNCR2820600912>3.0.CO;2-GSearch in Google Scholar

van den Bent MJ. Chemotherapy of oligodendroglial tumours: current developments. Forum (Genova) 2000; 10: 108-18.Search in Google Scholar

van den Bent MJ. New perspectives for the diagnosis and treatment of oligodendrogliomav. Expert Rev Anticancer Ther 2001; 1: 348-56.10.1586/14737140.1.3.348Search in Google Scholar

Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 2001; 19: 509-18.10.1200/JCO.2001.19.2.509Search in Google Scholar

Soffietti R. Chemotherapy of anaplastic oligodendroglial tumours. Expert Opin Pharmacother 2004; 5: 295-306.10.1517/14656566.5.2.295Search in Google Scholar

Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999; 17: 2762-71.10.1200/JCO.1999.17.9.2762Search in Google Scholar

Michotte A, Chaskis C, Sadones J, Veld PI, Neyns B. Primary leptomeningeal anaplastic oligodendroglioma with a 1p36-19q13 deletion: Report of a unique case successfully treated with Temozolomide. J Neurol Sci 2009; 287: 267-70.10.1016/j.jns.2009.08.047Search in Google Scholar

Morrison T, Bilbao JM, Yang G, Perry JR. Bony metastases of anaplastic oligodendroglioma respond to temozolomide. Can J Neurol Sci 2004; 31: 102-8.10.1017/S0317167100002912Search in Google Scholar

van den Bent MJ. Anaplastic oligodendroglioma and oligoastrocytoma. Neurol Clin 2007; 25: 1089-109.10.1016/j.ncl.2007.07.013Search in Google Scholar

Buckner JC, Reid JM, Wright K, Kaufmann SH, Erlichman C, Ames M, et al. Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group. Cancer 2003; 97: 2352-8.10.1002/cncr.11304Search in Google Scholar

Soffietti R, Nobile M, Rudà R, Borgognone M, Costanza A, Laguzzi E, et al. Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study. Cancer 2004; 100: 807-13.10.1002/cncr.20042Search in Google Scholar

Chamberlain MC, Johnston S. Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer 2009; 115: 1734-43.10.1002/cncr.24179Search in Google Scholar

Gadji M, Fortin D, Tsanaclis AM, Drouin R. Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas? Cancer Genet Cytogenet 2009; 194: 12-22.10.1016/j.cancergencyto.2009.05.004Search in Google Scholar

Stupp R, Hegi ME. Neuro-oncology: oligodendroglioma and molecular markers. Lancet Neurol 2007; 6: 10-2.10.1016/S1474-4422(06)70663-9Search in Google Scholar

Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001; 7: 839-45.Search in Google Scholar

Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J, et al. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 2002; 161: 313-9.10.1016/S0002-9440(10)64183-1Search in Google Scholar

Ducray F, Idbaih A, de Reyniès A, Bièche I, Thillet J, Mokhtari K, et al. Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer 2008; 7: 41.10.1186/1476-4598-7-41Search in Google Scholar

Riemenschneider MJ, Koy TH, Reifenberger G. Expression of oligodendrocyte lineage genes in oligodendroglial and astrocytic gliomas. Acta Neuropathol 2004; 107: 277-82.10.1007/s00401-003-0809-8Search in Google Scholar

Li H, Lu Y, Smith HK, Richardson WD. Olig1 and Sox10 interact synergistically to drive myelin basic protein transcription in oligodendrocytes. J Neurosci 2007; 27: 14375-82.10.1523/JNEUROSCI.4456-07.2007Search in Google Scholar

Aldape K, Burger PC, Perry A. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med 2007; 131: 242-51.10.5858/2007-131-242-CAOQLASearch in Google Scholar

Glioma meta-analysis trialists group. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359: 1011-8.10.1016/S0140-6736(02)08091-1Search in Google Scholar

van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006; 24: 2715-22.10.1200/JCO.2005.04.607816782911Search in Google Scholar

Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, et al. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol 2006; 24: 4746-53.10.1200/JCO.2006.06.389116954518Search in Google Scholar

Idbaih A, Omuro A, Ducray F, Hoang-Xuan K. Molecular genetic markers as predictors of response to chemotherapy in gliomas. Curr Opin Oncol 2007; 19: 606-11.10.1097/CCO.0b013e3282f075f317906460Search in Google Scholar

Fontaine D, Vandenbos F, Lebrun C, Paquis V, Frenay M. Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice. Rev Neurol (Paris) 2008; 164: 595-604.10.1016/j.neurol.2008.04.00218565359Search in Google Scholar

Sonabend AM, Lesniak MS. Oligodendrogliomas: clinical significance of 1p and 19q chromosomal deletions. Expert Rev Neurother 2005; 5: S25-32.10.1586/14737175.5.6.S2516274268Search in Google Scholar

Cankovic M, Mikkelsen T, Rosenblum ML, Zarbo RJ. A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue. Lab Invest 2007; 87: 392-7.10.1038/labinvest.370052017260000Search in Google Scholar

Mueller WC, von Deimling A. Gene regulation by methylation. Recent Results Cancer Res 2009; 171: 217-39.10.1007/978-3-540-31206-2_1319322547Search in Google Scholar

Norden AD, Wen PY. Glioma therapy in adults. Neurologist 2006; 12: 279-92.10.1097/01.nrl.0000250928.26044.4717122724Search in Google Scholar